PubRank
Search
About
G Vassal
Author PubWeight™ 51.62
‹?›
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study.
J Clin Oncol
2002
1.63
2
High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study.
Bone Marrow Transplant
1992
1.49
3
European collaboration in trials of new agents for children with cancer.
Eur J Cancer
2004
1.42
4
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma.
Ann Oncol
2003
1.36
5
Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood.
Int J Cancer
1998
1.32
6
Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution.
Bone Marrow Transplant
1999
1.23
7
Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma.
Cancer
2001
1.19
8
Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.
Clin Cancer Res
2000
1.17
9
Conduct of phase I trials in children with cancer.
J Clin Oncol
1998
1.16
10
Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy.
Ann Oncol
2007
1.09
11
Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model.
Proc Natl Acad Sci U S A
2000
1.06
12
Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients.
J Clin Endocrinol Metab
1987
1.05
13
Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
J Clin Oncol
1998
1.03
14
Neurofibromatosis 1 (NF1) mRNAs expressed in the central nervous system are differentially spliced in the 5' part of the gene.
Hum Mol Genet
1995
1.01
15
Outcome of flat bone sarcomas (other than Ewing's) in children and adolescents: a study of 25 cases.
Br J Cancer
2004
1.01
16
Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivity to irinotecan.
Oncogene
2006
1.00
17
Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial.
Eur J Cancer
2012
0.99
18
Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies.
Br J Cancer
2005
0.98
19
Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children.
Bone Marrow Transplant
1992
0.96
20
Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma.
Bone Marrow Transplant
2000
0.96
21
Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts.
Br J Cancer
2003
0.94
22
Temozolomide in paediatric high-grade glioma: a key for combination therapy?
Br J Cancer
2004
0.90
23
Treatment of stage IV-S neuroblastoma: a study of 34 cases treated between 1982 and 1987.
Med Pediatr Oncol
1991
0.89
24
Dose-finding designs in pediatric phase I clinical trials: comparison by simulations in a realistic timeline framework.
Contemp Clin Trials
2012
0.89
25
p53-dependent G2 arrest associated with a decrease in cyclins A2 and B1 levels in a human carcinoma cell line.
Br J Cancer
2000
0.89
26
Streptococcal septicaemia following autologous bone marrow transplantation in children treated with high-dose chemotherapy.
Bone Marrow Transplant
1991
0.87
27
Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study.
Br J Cancer
2001
0.86
28
Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Société Française d'Oncologie Pédiatrique.
J Clin Oncol
1993
0.86
29
In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
Bone Marrow Transplant
2003
0.85
30
Pharmacokinetics and antitumor effects of mitoxantrone after intratumoral or intraarterial hepatic administration in rabbits.
Cancer Chemother Pharmacol
1996
0.84
31
Chemotherapy in osteogenic sarcoma: the experience of the Pediatric Department of the Gustave Roussy Institute.
Cancer Treat Res
1993
0.84
32
Comparative genomic hybridization detects many recurrent imbalances in central nervous system primitive neuroectodermal tumours in children.
Br J Cancer
1999
0.83
33
[Granulosa cell tumors of the ovary in children and adolescents. Multicenter retrospective study in 40 patients aged 7 months to 22 years].
Arch Fr Pediatr
1992
0.83
34
[Carboxypeptidase-G2 rescue of methotrexate intoxication].
Bull Cancer
1998
0.82
35
Establishment and characterization of a human adrenocortical carcinoma xenograft model.
Endocrinology
2000
0.81
36
Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours.
Eur J Cancer
2007
0.81
37
A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours.
Br J Cancer
2006
0.79
38
Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy.
Pathol Oncol Res
1998
0.79
39
Human growth hormone gene transfer into tumor cells may improve cancer chemotherapy.
Cancer Gene Ther
2002
0.79
40
Individual dosing of carboplatin based on drug monitoring in children receiving high-dose chemotherapy.
Eur J Cancer
2003
0.78
41
Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma?
J Immunother
1999
0.78
42
High-dose chemotherapy in childhood brain tumours.
Childs Nerv Syst
1999
0.78
43
Stage IV neuroblastoma in patients over 1 year of age at diagnosis: consolidation of poor responders with combined busulfan, cyclophosphamide and melphalan followed by in vitro mafosfamide-purged autologous bone marrow transplantation.
Eur J Cancer
1997
0.77
44
The state of research into children with cancer across Europe: new policies for a new decade.
Ecancermedicalscience
2011
0.77
45
Autologous bone marrow transplantation in pediatric solid tumors: phase II studies.
Bone Marrow Transplant
1991
0.77
46
In vivo potentiation of radiation response by topotecan in human rhabdomyosarcoma xenografted into nude mice.
Clin Cancer Res
2000
0.77
47
High-dose chemotherapy containing busulfan followed by bone marrow transplantation in 24 children with refractory or relapsed non-Hodgkin's lymphoma.
Bone Marrow Transplant
1991
0.77
48
[Role of high-dose chemotherapy followed by bone marrow autograft in the treatment of metastatic Ewing's sarcoma in children].
Bull Cancer
1990
0.77
49
Brain tumours under the age of three. The price of survival. A retrospective study of 20 long-term survivors.
Acta Neurochir (Wien)
1990
0.77
50
Potentiation of tumour apoptosis by human growth hormone via glutathione production and decreased NF-kappaB activity.
Br J Cancer
2003
0.77
51
Radiosensitization after busulphan.
Lancet
1987
0.77
52
Molecular genetic studies of chromosome 11 and chromosome 22q DNA sequences in pediatric medulloblastomas.
J Neurooncol
1999
0.77
53
No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan.
Br J Cancer
2004
0.76
54
Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors.
Clin Pharmacol Ther
2007
0.76
55
Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma.
Ann Oncol
2002
0.76
56
[Statutory pediatric informations available for anticancer drugs: inventory and proposals].
Arch Pediatr
2002
0.75
57
Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations.
Br J Cancer
1999
0.75
58
Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
Bone Marrow Transplant
1996
0.75
59
[Methotrexate-ciprofloxacin interaction: report of two cases of severe intoxication].
Arch Pediatr
2001
0.75
60
[Potential role of antiangiogenic treatment in neuroblastoma].
Arch Pediatr
2009
0.75
61
[What is new in pediatric oncology?].
Arch Pediatr
2000
0.75
62
Previous conventional chemotherapy is the principal risk factor for immunoglobulin deficiency during the early post-ABMT period in children.
Bone Marrow Transplant
1996
0.75
63
[Pediatric aspects of anthracycline cardiotoxicity and practical implications for prevention].
Arch Pediatr
1995
0.75
64
[Acute lymphoblastic leukemia in Burkitt cells: clinical, therapeutic and prognostic aspects].
Nouv Rev Fr Hematol
1986
0.75
65
[Targeted therapies in pediatric oncology: a new therapeutic approach?].
Arch Pediatr
2005
0.75
66
Toxicity induced by chemotherapy mimicking cytomegalovirus gastritis.
Histopathology
1995
0.75
67
[Prophylaxis of Gram-positive infections after bone marrow graft. Controlled study of the 6-day administration of vancomycin. Intermediate analysis of 60 patients].
Pathol Biol (Paris)
1988
0.75
68
Busulfan and veno-occlusive disease of the liver.
Ann Intern Med
1990
0.75